Showing 6401-6410 of 8827 results for "".
- BTL Aesthetics Introduces Exilis Elitehttps://practicaldermatology.com/news/20130415-btl_aesthetics_introduces_exilis_elite/2459563/BTL Aesthetics recently introduced the Exilis ELITE, its next stage device for reducing wrinkles and treating skin laxity of the face and body. Optimizing the dynamic monopolar radiofrequency (RF) technology of the original Exilis system, the new ELITE platformoptimizes the monopolar radiofrequency
- FDA Approves New Corticosteroid Spray for Psoriasishttps://practicaldermatology.com/news/20130415-fda_approves_new_corticosteroid_spray_for_psoriasis/2459564/The FDA has approved Topicort® (desoximetasone) Topical Spray, 0.25%, for the treatment of plaque psoriasis. According manufacturer Taro Pharmaceuticals, Topicort Spray is indicated for patients 18 years of age or older.
- Dr. Yates Hair Science Group Adopts ARTAS Systemhttps://practicaldermatology.com/news/20130410-dr_yates_hair_science_group_adopts_artas_system/2459568/Restoration Robotics, Inc. installed its revolutionary ARTAS® System at the Dr. Yates Hair Science Group. The ARTAS System is the first and only FDA-cleared, physician-controlled, computer-assisted technology for hair transplantation.
- Rosacea Hinders Social Experiences For More Than 16 Million Americanshttps://practicaldermatology.com/news/20130409-rosacea_hinders_social_experiences_for_more_than_16_million_americans/2459570/Roughly half of rosacea patients refuse certain foods and drinks for fear of triggering a rosacea flare-up. That's according to numbers from the National Rosacea Society (NRS), which designated the month of April as Rosacea Awareness Month to alert the public to the early warning signs of rosacea. T
- Dr. Amy Forman Taub Partners With Mott 50https://practicaldermatology.com/news/20130408-dr_amy_forman_taub_partners_with_mott_50/2459572/Chicago-area board-certified dermatologist Amy Forman Taub, MD teamed up with Mott 50 to create a specially designed sun-protective shirt to be sold at her SKINFO Specialty Skincare Boutique. The breathable, long-sleeve navy Skin For Life shirt is pump
- Site Aims to Steer Patients to Physicians' Informationhttps://practicaldermatology.com/news/20130401-site_aims_to_steer_patients_to_physicians_information/2459577/Giving patients the proper information has always been important for physicians, and accessible handout literature has been the easiest ways to keep bad information out of their hands. But to keep pace with how quickly patients get their information, Vivacare allows physicians to enroll online free
- Skin Cancer Foundation Inducts Dr. Amy Forman Taub into its Amonette Circlehttps://practicaldermatology.com/news/20130327-skin_cancer_foundation_inducts_amy_forman_taub_md_into_its_amonette_circle/2459579/Amy Forman Taub, MD, was recently inducted into the Skin Cancer Foundation's Amonette Circle at the American Academy of Dermatology Annual Meeting in Miami, FL. Amonette Circle is a lifetime membership comprised of physicians who make an outstanding commitment to The Skin Cancer Foundation's mission
- Merz to Absorb Costs of New Excise Tax on Certain Medical Deviceshttps://practicaldermatology.com/news/20130321-merz_to_absord_costs_of_new_excise_tax_on_medical_devices/2459580/Merz Aesthetics announced that it does not intend to raise prices on medical devices, despite the new excise tax on the sale of certain medical devices of about 2.3 percent now going into effect, per the Patient Protection and Affordable Care Act. In a statement to clients and potential clients, Mer
- Valeant Pharmaceuticals to Acquire Obagi Medical Products for Approximately $344 Millionhttps://practicaldermatology.com/news/20130320-valeant_pharmaceuticals_to_acquire_obagi_medical_products_for_approximately_360_million/2459581/Valeant Pharmaceuticals has entered into an agreement to acquire Obagi Medical Products. The transaction values Obagi common stock at approximately $344 million and was unanimously approved by the Obagi Board of Directors. Under terms of the merger agreement, Valeant will commence a tender offer for
- Investigational Melanoma Agent Meets Endpoint in Phase 3 Trialhttps://practicaldermatology.com/news/20130320-investigational_melanoma_agent_meets_endpoint_in_phase_3_trial/2459582/New Phase 3 trial data found that Amgen's investigational melanoma agent talimogene laherparepvec met its primary endpoint of durable response rate for the treatment of unresected stage IIIB, IIIC, or IV melanoma. Researchers observed a statistically significant difference of 16 percent in DRR in pa